BIA
VRTX icon

Benchmark Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Benchmark Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$270K Buy
+556
New +$259K 0.17% 81
2022
Q1 		– Sell
-938
Closed -$206K – 160
2021
Q4 		$206K Buy
+938
New +$182K 0.17% 96

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Benchmark Investment Advisors's VRTX Position: Q1 2025 in Review

Benchmark Investment Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2025: 556 shares worth $270K. The stake represents 0.17% of the portfolio and ranks #81 among its holdings. This is a return to the name: Benchmark Investment Advisors previously reported a position in VRTX as recently as Q4 2021.

Benchmark Investment Advisors first reported a position in VRTX in Q4 2021 and has held it in 2 quarters since. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Benchmark Investment Advisors held 556 shares of Vertex Pharmaceuticals worth $270K as of Q1 2025.
  • Vertex Pharmaceuticals was a new Benchmark Investment Advisors position in Q1 2025.
  • Vertex Pharmaceuticals made up 0.17% of Benchmark Investment Advisors's portfolio in Q1 2025, its #81 holding.
  • Benchmark Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Benchmark Investment Advisors's 13F filing for Q1 2025, filed 15 May 2025.